Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report)'s stock price shot up 9.4% during mid-day trading on Wednesday . The company traded as high as $11.58 and last traded at $11.45. 555,834 shares changed hands during trading, a decline of 76% from the average session volume of 2,289,147 shares. The stock had previously closed at $10.47.
Analyst Ratings Changes
Several research analysts have commented on AVXL shares. HC Wainwright raised their target price on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, December 26th. D. Boral Capital reaffirmed a "buy" rating and set a $46.00 target price on shares of Anavex Life Sciences in a report on Monday.
Read Our Latest Report on AVXL
Anavex Life Sciences Trading Up 8.2 %
The stock has a market cap of $960.97 million, a PE ratio of -22.66 and a beta of 0.70. The firm has a fifty day simple moving average of $9.61 and a two-hundred day simple moving average of $7.10.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. Equities analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.
Institutional Trading of Anavex Life Sciences
Hedge funds have recently made changes to their positions in the stock. Orion Capital Management LLC increased its stake in Anavex Life Sciences by 666.7% in the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock valued at $65,000 after acquiring an additional 10,000 shares during the last quarter. PVG Asset Management Corp bought a new position in shares of Anavex Life Sciences during the 3rd quarter valued at about $74,000. Atria Investments Inc bought a new position in shares of Anavex Life Sciences during the 3rd quarter valued at about $76,000. BNP Paribas Financial Markets raised its holdings in shares of Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock valued at $86,000 after buying an additional 7,421 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Anavex Life Sciences by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company's stock worth $93,000 after buying an additional 6,366 shares during the last quarter. 31.55% of the stock is owned by institutional investors.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
